Low-Voltage Area Ablation for Persistent Atrial Fibrillation
Pablo B. Nery, George A. Wells, Girish M. Nair, Vidal Essebag, Jacqueline E. Joza, Jorge A. Wong, George D. Veenhuyzen, Atul Verma, Isabelle Nault, Jason Andrade, John L. Sapp, Allan Cameron Skanes, Mehrdad Golian, Laurent Macle, Mouhannad M. Sadek, Paul Angaran, Markus Bernardus Sikkel, Charles Dussault, Derek Yung, Jeff S. Healey, Simon Peter Hansom, Calum J. Redpath, Damian Redfearn, Francisco Daniel Ramirez, Klein Andres, David H. Birnie
In the authors' words
This journal does not let us republish the full abstract. Here are the two sentences Pipette selected, quoted from it. Read the rest at the publisher.
Conclusions and Relevance In this study, among patients with persistent AF, adjunctive LVA ablation did not significantly reduce atrial arrhythmia recurrence in the overall population over a mean 21-month follow-up.
A prespecified principal subgroup analysis of patients with LVA suggested that adjunctive LVA ablation was consistent with reduced recurrence of atrial arrhythmias in this group.
Appeared: Tuesday, November 10. JAMA. Peer-reviewed journal.
More on Treatments & drugs that day
Retatrutide Once Weekly in Adults with Knee Osteoarthritis Pain and Obesity
Background: The efficacy and safety of retatrutide, an investigational triple agonist of glucosedependent insulinotropic polypeptide, glucagon-like peptide 1, and glucagon receptors for painful knee osteoarthritis (OA) in people with obesity are unknown.Methods: Two phase 3 trials enrolled adults with painful knee OA and BMI ≥27 kg/m 2 without diabetes.Participants were randomly assigned to once-weekly subcutaneous retatrutide (TRIUMPH-4, N=445: 9-mg, 12-mg; TRIUMPH-1-OA, N=574: 4-mg, 9-mg, 12-mg) or placebo.TRIUMPH-4 co-primary endpoints were change in WOMAC pain score (range, 0-10, higher=more pain) and percent change in bodyweight at week 68; TRIUMPH-1-OA primary endpoint was change in WOMAC pain score at week 80.For non-pain-related endpoints, intercurrent events were handled by a treatment policy strategy (treatment-regimen estimand [TRE]).For pain-related outcomes, a hybrid-treatment estimand was applied with a hypothetical strategy for participants with intercurrent events suggesting treatment failure and treatment policy strategy elsewhere.We also report an intention-to-treat estimand that applied a treatment policy strategy for all intercurrent events (hereafter ITT).Results: In TRIUMPH-4 (68 weeks), mean change in WOMAC pain (hybrid-treatment estimand) was -3.96 (9-mg), -3.74 (12-mg) and -2.12 (placebo) (difference vs. placebo [95% CI] -1.83 [-2.37,-1.30],-1.61 [-2.16,-1.07],respectively); differences by ITT estimand: -1.70 [-2.19,-1.22];-1.38 [-1.91,-0.85])(P <0.001).Mean percent change in bodyweight was -20.0%(9-mg), -23.7% (12-mg) and -4.6% (placebo) (differences: -15.4 [-18.7,-12.1];-19.2 [-22.4,-15.9])(P <0.001).In TRIUMPH-1-OA (80 weeks), mean change in WOMAC pain (hybrid-treatment estimand) was -3.22 (4-mg), -3.48 (9-mg), -3.64 (12-mg) and -1.87 (placebo) (differences: -1.35 [-1.92,-0.78];-1.61 [-2.20,-1.02];-1.77 [-2.34,-1.20]);and differences by ITT estimand: -0.96 [-1.61,-0.30];-1.41 [-2.07,-0.75];-1.64 [-2.26,-1.02])(P≤0.005).In both trials, serious adverse events (AEs) were more common with retatrutide than placebo, and gastrointestinal AEs were most common.Conclusions: In participants with painful knee OA and obesity, retatrutide treatment resulted in significant reductions in both WOMAC pain scores and bodyweight.(Funded by Eli Lilly and Company; TRIUMPH-4 ClinicalTrials.gov:NCT05931367; TRIUMPH-1 ClinicalTrials.gov:NCT05929066) Osteoarthritis (OA), a progressive joint disease, often includes pain that limits quality of life and confers substantial socioeconomic burdens on patients, healthcare systems, and society.[1][2][3] Obesity is a risk factor in both OA onset and progression.[1][2][3] Excess bodyweight increases mechanical loading on weight-bearing joints; further, increased joint stress accelerates cartilage degeneration and possible malalignment.1,3,4 Excess adiposity may also contribute to a systemic, low-grade inflammatory state.5 Weight reduction is considered an important component of knee OA management; each pound of bodyweight lost is associated with an approximately 4-fold load reduction across the knee.6 Biomechanical and clinical benefits increase with weight loss; progressively greater weight reduction is associated with lower maximum knee compressive forces and greater symptom improvements.7 Clinical guidelines include weight reduction alongside exercise, pharmacologic therapies such as nonsteroidal anti-inflammatory agents, intra-articular injections, and surgical interventions.8,9 Current pharmacologic therapies may provide modest efficacy but limited tolerability and safety.A study of semaglutide suggested improved knee OA pain, 10 highlighting the possibility that additional obesity therapeutics might address both excess bodyweight and knee OA symptoms.Retatrutide is an investigational triple-receptor agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1 (GLP-1), and glucagon receptors.In phase 2 clinical trials in patients with obesity, retatrutide demonstrated average weight reductions from 8.7%-24.2%,versus 2.1% with placebo (percentage point difference: -6.6 to -22.1), at 48 weeks.11 The two trials presented here, one published in part previously, 12 evaluated the efficacy, tolerability, and safety of once-weekly injectable retatrutide in adults with painful knee OA and obesity.
Thomas J. Schnitzer, D.J. Hunter, P. Conaghan and 7 more — New England Journal of Medicine
Peer-reviewed journalReal-world usesPLA2 inhibitor-loaded nanoparticles mitigate spontaneous osteoarthritis in guinea pigs
Collectively, our findings identify sPLA2 as a key driver of spontaneous OA and establish nanoparticle-mediated sPLA2 inhibition as a promising disease-modifying strategy for age-related OA.
Q. Liang, Q. He, Y. Xu and 11 more — bioRxiv
PreprintReal-world useSafety and tolerability of RJx-01 to maintain muscle integrity in patients following hospitalisation with an acute exacerbation of COPD (MINT-COPD): protocol for a phase IIa randomised double-blind placebo-controlled trial
The primary aim of this study is to evaluate the safety and tolerability of RJx-01 compared with placebo following hospitalisation with an acute exacerbation of COPD (AECOPD), when acute deterioration of skeletal muscle integrity is observed.
I. N. Qureshi, G. Mills, H. J. C. McAuley and 13 more — medRxiv
PreprintEffectiveness of AI-Supported Holistic Health Management Through PREVERY's Digital Health Promotion and Prevention Program: A Prospective Before-and-After Observational Study
Conclusion: PREVERY seems to be an effective prevention program to increase psychological capital together with self-reported current health status, health awareness, health literacy, and self-efficacy, while at the same time reducing perceived stress.
M. Ringleb, T. Trampert, T. Trampert and 1 more — medRxiv
PreprintBold claims, read criticallyReal-world use